ReviewFrontiers in pharmacology2020
Modeling and Targeting Alzheimer's Disease With Organoids.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 104 citations in OpenAlex.
- Combating ageing beyond the cell: Emerging roles of extracellular proteostasis.The FEBS journal · 2026Review
- Review
- Brain organoids as precision models for neurodegenerative diseases: from disease modeling to drug discovery.Frontiers in neuroscience · 2026Review
- Article
- 3D Printing for Neural Repair: Bridging the Gap in Regenerative Medicine.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Interrogating the regulatory epigenome of cellular senescence.Cellular and molecular life sciences : CMLS · 2025Review
- CRISPR/Cas9 and iPSC-Based Therapeutic Approaches in Alzheimer's Disease.Antioxidants (Basel, Switzerland) · 2025Review
- Engineering blood-brain barrier microphysiological systems to model Alzheimer's disease monocyte penetration and infiltration.Biomaterials science · 2025Article
- Beyond Transgenic Mice: Emerging Models and Translational Strategies in Alzheimer's Disease.International journal of molecular sciences · 2025Review
- A 3D human iPSC-derived multi-cell type neurosphere system to model cellular responses to chronic amyloidosis.Journal of neuroinflammation · 2025Article
- Brain organoid model systems of neurodegenerative diseases: recent progress and future prospects.Frontiers in neuroscience · 2025Review
- Medical embryology and regenerative medicine: research and applications in clinical practice.Frontiers in cell and developmental biology · 2025Review
- Effects of amyloid-β-mimicking peptide hydrogel matrix on neuronal progenitor cell phenotype.Acta biomaterialia · 2024Article
- Insights on the Use of Transgenic Mice Models in Alzheimer's Disease Research.International journal of molecular sciences · 2024Review
- Novel Approaches to Studying SLC13A5 Disease.Metabolites · 2024Review
- Alzheimer's Disease from Modeling to Mechanism Research.Advances in neurobiology · 2024Review
- Cerebral Organoid Arrays for Batch Phenotypic Analysis in Sections and Three Dimensions.International journal of molecular sciences · 2023Article
- Soluble NKG2D ligands impair CD8Oncology letters · 2023Article
- Functional bioengineered tissue models of neurodegenerative diseases.Biomaterials · 2023Review
- Molecular Insights into Cell Type-specific Roles in Alzheimer's Disease: Human Induced Pluripotent Stem Cell-based Disease Modelling.Neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human neurodegenerative diseases, such as Alzheimer's disease (AD), are not easily modeled
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.